Merck & Co Inc
6MK
Company Profile
Business description
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. In cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 53% of the company's 2025 sales were generated from US human health (pharmaceuticals and vaccines).
Contact
126 East Lincoln Avenue
RahwayNJ07065
USAT: +1 908 740-4000
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2026
Employees
75,000
Stocks News & Analysis
stocks
Two cheap wide moat ASX shares
These shares are trading at a discount to our fair value discount and have sustainable competitive advantages.
stocks
Anthropic: Are the shares undervalued given the IPO pricing range?
There may be meaningful upside as Anthropic is pricing its stock as a reflection of current sentiment, not the company’s fundamentals.
stocks
Valuation looks stretched for ASX healthcare share
Strong fundamentals meet a demanding valuation.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,247.10 | 44.20 | -0.48% |
| CAC 40 | 8,332.87 | 54.28 | 0.66% |
| DAX 40 | 26,662.77 | 315.32 | 1.20% |
| Dow JONES (US) | 52,486.49 | 254.60 | 0.49% |
| FTSE 100 | 10,835.47 | 83.88 | 0.78% |
| HKSE | 24,315.92 | 241.12 | -0.98% |
| NASDAQ | 25,466.19 | 400.32 | 1.60% |
| Nikkei 225 | 61,248.59 | 789.01 | 1.31% |
| NZX 50 Index | 14,249.47 | 69.61 | 0.49% |
| S&P 500 | 7,619.38 | 98.45 | 1.31% |
| S&P/ASX 200 | 9,110.50 | 42.70 | -0.47% |
| SSE Composite Index | 3,680.64 | 16.92 | 0.46% |